From: 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment
Baseline (Mean ± SD)
Post-RT (Mean ± SD)
p
IIEF-5 score
13.2 ± 7.6
13 ± 7.8
0,23
ICIQ-SF score
0.8 ± 2
1.1 ± 2.5
0,33